The microalgae feed developed by the company can inhibit the growth of Vibrio, a major shrimp pathogen, thereby significantly reducing the large amount of antibiotics used in farming shrimp larvae and providing healthier edible shrimp products. Another product is the production of heterotrophic algal astaxanthin. Because its production capacity is far greater than that of *Haematococcus pluvialis* currently used commercially, it can significantly reduce the production cost of algal astaxanthin, thereby achieving higher profits. Currently, the company has established partnerships with upstream, midstream, and downstream manufacturers in this field, actively expanding its distribution channels, with the aim of securing a place in the domestic and international microalgae aquaculture feed and health food markets.
(The content above was translated by AI.)